Valneva's Lyme Shot Nears EU Verdict as Pipeline Readouts and Cost Cuts Converge

Valneva awaits an EU review of its Pfizer-partnered Lyme vaccine and Q3 Shigella data, while restructuring to preserve cash after a weak first half.

Valneva finds itself at a crossroads where regulatory ambition meets balance-sheet reality. The French vaccine developer, whose shares trade at EUR 2.83 and have shed 24 percent since the start of the year, is betting that a pair of near-term catalysts — a European review of its Lyme disease candidate and fresh Shigella data — can shift investor attention away from a bruising first half.

At the heart of that bet sits PF-07307405, the Lyme vaccine developed alongside Pfizer. Roughly two weeks ago, the European Medicines Agency validated the marketing application for the shot, a milestone that has nonetheless been followed by a 2.0 percent slide in the stock. The filing leans on the Phase 3 VALOR trial, which enrolled participants aged five and older and demonstrated efficacy above 70 percent. Pfizer has described the safety profile as clean, with no concerning signals. Should the review succeed, Valneva and its U.S. partner would enter a market with no approved human Lyme vaccine in Europe — a first-mover position that underpins much of the company's medium-term growth case.

Timing appears to favor Europe. According to media reports, Pfizer expects regulatory decisions from both U.S. and European authorities within a year, with the European side likely to conclude first. For Valneva, a green light would mark entry into entirely unoccupied territory.

Shigella Data Due This Quarter

While the Lyme program commands the spotlight, a second readout is approaching. S4V2, the Shigella vaccine candidate being advanced with LimmaTech Biologics AG, is under investigation in two sponsored trials: a Phase 2 study assessing safety and immunogenicity in young children, and a Phase 2b controlled human infection study in healthy adults. Results from both are anticipated during the third quarter of 2026. A favorable outcome would reinforce Valneva's early-stage pipeline and broaden its technological reach beyond marketed products. The data will also determine whether the company takes over responsibility for late-stage clinical development.

Elsewhere in the portfolio, the Chikungunya vaccine continues to gain ground. A pilot campaign with Brazil's Instituto Butantan has reportedly vaccinated around 50,000 adults to date. The locally manufactured version, VLA1555, secured approval in May 2026.

Restructuring to Preserve Cash

Against these scientific hopes, the operational picture remains strained. First-half results, released more than a month ago, laid bare the pressure: total revenue fell to EUR 65.8 million from EUR 97.6 million a year earlier. The decline stemmed from lower production and sales volumes as well as one-off items tied to the IXCHIQ vaccine, including contract termination costs and inventory write-downs. Product sales for the six months came in at EUR 64.0 million, while cash and liquid resources stood at EUR 121.5 million as of June 30, 2026.

Management is responding with a global restructuring initiative unveiled about two weeks ago — a move that has since knocked 4.2 percent off the share price. The plan centers on significant headcount reductions and a streamlining of global operations, alongside a tightening of research activities. A further lever: an agreement to sell the Nantes site for EUR 6.2 million, with completion scheduled for September 2026.

The company has left its full-year 2026 guidance untouched, targeting product revenue of EUR 135 million to EUR 150 million. Executives are also aiming to lift gross margins on products in the second half. Whether those commitments prove enough may hinge on the clinical and regulatory milestones now crowding the calendar — and on whether investors, watching a stock that sits 9.6 percent above its 50-day moving average of EUR 2.58, are willing to wait for the verdicts.